Want to see HK:2410 full AI Analyst Report?
Top Page
TYK Medicines, Inc. Class H
(2410)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$3.00
▼(-76.80% Downside)
Action:Reiterated
Date:09/23/26
The score is primarily held back by weak financial performance (heavy ongoing losses and material cash burn with continued funding dependence) and bearish technicals (price well below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
Manageable Leverage
Recent leverage appears manageable rather than excessive, which preserves some financial flexibility for research and development. Although the company remains loss-making, its current debt burden is not identified as over-geared, reducing near-term balance-sheet pressure.
Negative Factors
Persistent Cash Burn
Heavy operating and free-cash-flow burn means the business is not self-funding its development activities. Continued negative cash generation can consume available resources, restrict strategic flexibility, and increase dependence on future financing to maintain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Recent leverage appears manageable rather than excessive, which preserves some financial flexibility for research and development. Although the company remains loss-making, its current debt burden is not identified as over-geared, reducing near-term balance-sheet pressure.
Read all positive factors
TYK Medicines, Inc. Class H (2410) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.17B
Dividend YieldN/A
Average Volume (3M)680.58K
Price to Earnings (P/E)―
Beta (1Y)1.81
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees184
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding380,065,830
10 Day Avg. Volume222,050
30 Day Avg. Volume680,579
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)15.38
Price to Sales (P/S)0.00
P/FCF Ratio-17.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)HK$504.00M
TYK Medicines, Inc. Class H Business Overview & Revenue Model
Company Description
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug can...
TYK Medicines, Inc. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
37
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 107.00K | 0.00 | 44.24M |
| Gross Profit | 0.00 | -24.37M | 14.00K | -27.66M | 20.04M |
| EBITDA | -329.78M | -289.17M | -346.03M | -346.80M | -292.22M |
| Net Income | -212.49M | -292.01M | -386.95M | -382.43M | -310.99M |
Balance Sheet | |||||
| Total Assets | 768.55M | 780.07M | 915.69M | 573.14M | 558.36M |
| Cash, Cash Equivalents and Short-Term Investments | 201.96M | 367.44M | 460.46M | 192.83M | 243.49M |
| Total Debt | 149.63M | 152.81M | 176.85M | 1.33B | 82.33M |
| Total Liabilities | 507.79M | 493.13M | 443.13M | 1.45B | 1.06B |
| Stockholders Equity | 260.96M | 286.79M | 469.09M | -884.48M | -505.94M |
Cash Flow | |||||
| Free Cash Flow | -268.96M | -255.18M | -381.87M | -278.20M | -308.23M |
| Operating Cash Flow | -212.86M | -215.77M | -308.25M | -200.94M | -220.05M |
| Investing Cash Flow | 167.09M | 35.95M | -135.86M | 73.01M | -158.16M |
| Financing Cash Flow | 116.38M | 126.38M | 632.08M | 224.00M | 351.14M |
TYK Medicines, Inc. Class H Technical Analysis
Negative
12.93
Price Trends
4.21
Negative
5.53
Negative
8.24
Negative
Market Momentum
-0.33
Negative
36.72
Neutral
24.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2410, the sentiment is Negative. The current price of 12.93 is above the 20-day moving average (MA) of 3.43, above the 50-day MA of 4.21, and above the 200-day MA of 8.24, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 36.72 is Neutral, neither overbought nor oversold. The STOCH value of 24.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2410.
TYK Medicines, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% | |
64 Neutral | HK$2.60B | 12.92 | 4.45% | 0.27% | 7.38% | 7.90% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$3.62B | 6.01 | 47.76% | ― | 286.20% | ― | |
48 Neutral | HK$2.55B | -15.11 | -7.65% | ― | 21.23% | 36.89% | |
43 Neutral | HK$1.62B | 1.61 | -64.89% | ― | -99.15% | ― | |
42 Neutral | HK$1.17B | -4.66 | -77.60% | ― | ― | ― |
* General Sector Average
HK:2410
TYK Medicines, Inc. Class H
3.09
-12.14
-79.73%
HK:9996
Peijia Medical Ltd.
3.77
-2.22
-37.06%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.60
-2.66
-36.64%
HK:1873
Viva Biotech Holdings
1.25
-1.14
-47.70%
HK:2197
Clover Biopharmaceuticals Ltd.
1.25
-0.99
-44.20%
HK:2633
Jacobson Pharma Corporation Limited
0.94
-0.42
-30.74%
TYK Medicines, Inc. Class H Corporate Events
TYK Medicines Shareholders Back Board Re-elections and Governance Changes
Oct 16, 2026
Shareholders of TYK Medicines, Inc. convened for the company’s second extraordinary general meeting of 2026 in Shanghai, where all directors attended either in person or electronically. The meeting complied with PRC Company Law and the firm&...
TYK Medicines Calls October EGM to Refresh Board and Amend Articles
Sep 30, 2026
TYK Medicines, Inc. has called a second extraordinary general meeting for October 16, 2026 in Shanghai to vote on the re-election of several board members, including executive and non-executive directors, as well as independent non-executive direc...
TYK Medicines Subscription Deal With Qilu Lapses but Collaboration Continues
Sep 20, 2026
TYK Medicines, Inc. announced that its subscription agreement with Qilu for the proposed issuance of 63,222,744 H shares has lapsed after certain conditions precedent were not fulfilled or waived by the revised long stop date of September 20, 2026...
TYK Medicines Sets Book Closure for 2026 Extraordinary General Meeting
Sep 18, 2026
TYK Medicines, Inc. has announced administrative arrangements for its 2026 second extraordinary general meeting, where shareholders will consider proposed amendments to the company’s articles of association and the re-election of directors. ...
TYK Medicines CEO Boosts Stake With New H-Share Purchases
Sep 10, 2026
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company by acquiring 635,000 H shares on the open market between September 8 and 10, 2026, for abou...
TYK Medicines CEO Boosts Personal Stake While Upholding Public Float
Sep 8, 2026
TYK Medicines, Inc. has disclosed that its chairman, executive director and chief executive officer, Dr. Wu Yusheng, has increased his stake in the company through open-market share purchases funded by his personal resources. He has indicated that...
TYK Medicines Wins Conditional China Nod for Next‑Generation Lung Cancer Drug
Aug 27, 2026
TYK Medicines, Inc. announced that its self‑developed Asandeutertinib Mesylate Tablets (TY‑9591), a next‑generation, irreversible and highly selective EGFR‑TKI, has received conditional marketing approval from China’s...
TYK Medicines Extends Deadline for Major H-Share Subscription Deal
Aug 20, 2026
TYK Medicines, Inc., a PRC-incorporated biopharmaceutical company listed in Hong Kong under stock code 2410, is building its business around licensing and collaboration deals and the issuance of H shares under general mandates. The company’s...
TYK Medicines Clarifies Board Structure and Committee Roles
Aug 17, 2026
TYK Medicines, Inc., a Hong Kong-listed pharmaceutical and biotechnology company incorporated in the People’s Republic of China, has structured its board with executive, non-executive and independent non-executive directors to support its re...
TYK Medicines Narrows Interim Loss as Other Income Surges Despite Higher R&D Spend
Aug 17, 2026
TYK Medicines, Inc. reported an unaudited total comprehensive loss of RMB26.9 million for the six months ended June 30, 2026, a sharp improvement from a RMB114.1 million loss a year earlier, supported by a strong rise in other income and gains to ...
TYK Medicines reshapes board roles and plans director re-election
Aug 17, 2026
TYK Medicines, Inc. announced the resignation of non-executive director Dr. Jiang Mingyu, who stepped down effective August 17, 2026 to focus on other business endeavors, and confirmed there were no disputes or claims related to his departure. Con...
TYK Medicines Schedules Board Meeting to Approve Interim Results and Consider Dividend
Aug 5, 2026
TYK Medicines, Inc., a PRC-based pharmaceutical company listed in Hong Kong under stock code 2410, operates within the biopharmaceutical and healthcare sector, leveraging mainland China’s research base and Hong Kong’s capital markets. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.